{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:28:25Z","timestamp":1793053705853,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370775"],"award-info":[{"award-number":["82370775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570905"],"award-info":[{"award-number":["82570905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009579","name":"Health Department of Sichuan Province","doi-asserted-by":"publisher","award":["ZH2023-102"],"award-info":[{"award-number":["ZH2023-102"]}],"id":[{"id":"10.13039\/501100009579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77483-3","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:02:49Z","timestamp":1788890569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5024-2841","authenticated-orcid":false,"given":"Qiyou","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-8545","authenticated-orcid":false,"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhaoran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-9645","authenticated-orcid":false,"given":"Bo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8170-5587","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"77483_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41585-022-00684-0","volume":"20","author":"MJ Connor","year":"2023","unstructured":"Connor, M. J. et al. Landmarks in the evolution of prostate biopsy. Nat. Rev. Urol. 20, 241\u2013258 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"77483_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","volume":"4","author":"V Panebianco","year":"2021","unstructured":"Panebianco, V. et al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur. Urol. Oncol. 4, 868\u2013876 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"77483_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey, B. et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur. Urol. 76, 340\u2013351 (2019).","journal-title":"Eur. Urol."},{"key":"77483_CR4","first-page":"Cd012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost, F. H. et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.  Cochrane Database Syst. Rev. 4, Cd012663 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"77483_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/jmri.27546","volume":"54","author":"KJ Park","year":"2021","unstructured":"Park, K. J., Choi, S. H., Kim, M. H., Kim, J. K. & Jeong, I. G. Performance of prostate imaging reporting and data system version 2.1 for diagnosis of prostate cancer: a systematic review and meta-analysis. J. Magn. Reson. Imaging.: JMRI 54, 103\u2013112 (2021).","journal-title":"J. Magn. Reson. Imaging.: JMRI"},{"key":"77483_CR6","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3348\/kjr.2020.0837","volume":"22","author":"HS Kim","year":"2021","unstructured":"Kim, H. S., Kwon, G. Y., Kim, M. J. & Park, S. Y. Prostate Imaging-reporting and data system: comparison of the diagnostic performance between version 2.0 and 2.1 for prostatic peripheral zone. Korean J. Radiol. 22, 1100\u20131109 (2021).","journal-title":"Korean J. Radiol."},{"key":"77483_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72544-z","volume":"10","author":"MM Rudolph","year":"2020","unstructured":"Rudolph, M. M. et al. Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer. Sci. Rep. 10, 15982 (2020).","journal-title":"Sci. Rep."},{"key":"77483_CR8","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis.  N. Engl. J. Med. 378, 1767\u20131777 (2018).","journal-title":"N. Engl. J. Med."},{"key":"77483_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot, M. et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis.  N. Engl. J. Med. 382, 917\u2013928 (2020).","journal-title":"N. Engl. J. Med."},{"key":"77483_CR10","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210413","volume":"95","author":"S Ippoliti","year":"2022","unstructured":"Ippoliti, S. et al. Optimal biopsy approach for detection of clinically significant prostate cancer.  Br. J. Radiol. 95, 20210413 (2022).","journal-title":"Br. J. Radiol."},{"key":"77483_CR11","doi-asserted-by":"crossref","unstructured":"Wu Q., et al. Is ipsilateral systematic biopsy combined with targeted biopsy the optimal substitute for bilateral systematic biopsy combined with targeted biopsy: a systematic review and meta-analysis. Urol. Oncol. 43, 307\u2013317 2024.","DOI":"10.1016\/j.urolonc.2024.11.023"},{"key":"77483_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eururo.2016.08.004","volume":"71","author":"M Borghesi","year":"2017","unstructured":"Borghesi, M. et al. Complications after systematic, random, and image-guided prostate biopsy. Eur. Urol. 71, 353\u2013365 (2017).","journal-title":"Eur. Urol."},{"key":"77483_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.euo.2023.12.002","volume":"7","author":"X Jiang","year":"2024","unstructured":"Jiang, X. et al. Comparison of regional saturation biopsy, targeted biopsy, and systematic biopsy in patients with prostate-specific antigen levels of 4-20 ng\/ml: a prospective, single-center, randomized controlled trial. Eur. Urol. Oncol. 7, 944\u2013953 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"77483_CR14","doi-asserted-by":"crossref","unstructured":"Sanguedolce, F. et al. Regional versus systematic biopsy in addition to targeted biopsy: results from a systematic review and meta-analysis. Eur. Urol. Oncol. 8, 534\u2013543 2024.","DOI":"10.1016\/j.euo.2024.10.006"},{"key":"77483_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00345-022-04272-0","volume":"41","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study. World J. Urol. 41, 455\u2013461 (2023).","journal-title":"World J. Urol."},{"key":"77483_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102853","volume":"35","author":"T Long Depaquit","year":"2025","unstructured":"Long Depaquit, T. et al. PI-RADS 3 MRI lesions: are biopsies still necessary?  Fr. J. Urol. 35, 102853 (2025).","journal-title":"Fr. J. Urol."},{"key":"77483_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/JU.0000000000001832","volume":"206","author":"AG Raman","year":"2021","unstructured":"Raman, A. G. et al. Optimizing spatial biopsy sampling for the detection of prostate cancer.  J. Urol. 206, 595\u2013603 (2021).","journal-title":"J. Urol."},{"key":"77483_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2024.102572","volume":"34","author":"F Taha","year":"2024","unstructured":"Taha, F. et al. PIRADS\u22654 MRI lesion: is performing systematic biopsies still essential for detecting clinically significant prostate cancer? Fr. J. Urol. 34, 102572 (2024).","journal-title":"Fr. J. Urol."},{"key":"77483_CR19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20191050","volume":"94","author":"A Wadera","year":"2021","unstructured":"Wadera, A. et al. Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis.  Br. J. Radiol. 94, 20191050 (2021).","journal-title":"Br. J. Radiol."},{"key":"77483_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86, 148\u2013163 (2024).","journal-title":"Eur. Urol."},{"key":"77483_CR21","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/JS9.0000000000002122","volume":"111","author":"J Zhao","year":"2025","unstructured":"Zhao, J. et al. Decade-long insights into transperineal prostate biopsy in a West China population: temporal trend, targeted and repeat biopsies, and pathological characterization: a comparative study - retrospective cohort. Int. J. Surg. 111, 1636\u20131641 (2025).","journal-title":"Int. J. Surg."},{"key":"77483_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41391-023-00729-4","volume":"27","author":"Q Wu","year":"2024","unstructured":"Wu, Q. et al. Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 27, 212\u2013221 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"77483_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.1058288","volume":"9","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: study protocol for a randomized controlled trial. Front. Surg. 9, 1058288 (2022).","journal-title":"Front. Surg."},{"key":"77483_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4103\/aja202288","volume":"25","author":"CC Zhang","year":"2023","unstructured":"Zhang, C. C. et al. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-na\u00efve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml(\u22121) to 10 ng ml(\u22121). Asian J. Androl. 25, 492\u2013498 (2023).","journal-title":"Asian J. Androl."},{"key":"77483_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102121","volume":"22","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. Transperineal 3-core magnetic resonance imaging ultrasound fusion targeted plus laterally 6-core systematic biopsy in prostate cancer diagnosis. Clin. Genitourin. cancer 22, 102121 (2024).","journal-title":"Clin. Genitourin. cancer"},{"key":"77483_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/pros.24669","volume":"84","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: real-world insights from a high-volume center in southwest China.  Prostate 84, 539\u2013548 (2024).","journal-title":"Prostate"},{"key":"77483_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2024.04.001","volume":"64","author":"J Ye","year":"2024","unstructured":"Ye, J. et al. The impact of prostate volume on prostate cancer detection: comparing magnetic resonance imaging with transrectal ultrasound in biopsy-na\u00efve men. Eur. Urol. open Sci. 64, 1 (2024).","journal-title":"Eur. Urol. open Sci."},{"key":"77483_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103164","volume":"82","author":"Q Wu","year":"2025","unstructured":"Wu, Q. et al. Optimizing the strategies to perform prostate biopsy in MRI-positive patients: a systematic review and network meta-analysis. EClinicalMedicine 82, 103164 (2025).","journal-title":"EClinicalMedicine"},{"key":"77483_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eururo.2017.02.021","volume":"73","author":"W Venderink","year":"2018","unstructured":"Venderink, W. et al. Results of targeted biopsy in men with magnetic resonance imaging lesions classified equivocal, likely or highly likely to be clinically significant prostate cancer. Eur. Urol. 73, 353\u2013360 (2018).","journal-title":"Eur. Urol."},{"key":"77483_CR30","first-page":"11830","volume":"95","author":"D Ara\u00fajo","year":"2023","unstructured":"Ara\u00fajo, D. et al. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center. Archivio Ital. di urologia, Androl. organo ufficiale [di] Soc. Ital. di Ecogr. urologica e nefrologica 95, 11830 (2023).","journal-title":"Archivio Ital. di urologia, Androl. organo ufficiale [di] Soc. Ital. di Ecogr. urologica e nefrologica"},{"key":"77483_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41391-018-0065-6","volume":"21","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen, N. J. et al. Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications. Prostate Cancer Prostatic Dis. 21, 573\u2013578 (2018).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"77483_CR32","doi-asserted-by":"crossref","unstructured":"Gomez-Gomez, E. et al. Does adding standard systematic biopsy to targeted prostate biopsy in PI-RADS 3 to 5 lesions enhance the detection of clinically significant prostate cancer? Should all patients with PI-RADS 3 undergo targeted biopsy? Diagnostics 11, 1335 (2021).","DOI":"10.3390\/diagnostics11081335"},{"key":"77483_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41391-022-00620-8","volume":"26","author":"J-P Noujeim","year":"2022","unstructured":"Noujeim, J.-P. et al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. Prostate Cancer Prostatic Dis. 26, 575\u2013580 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"77483_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4103\/iju.iju_147_23","volume":"39","author":"SK Pratihar","year":"2023","unstructured":"Pratihar, S. K. et al. Prostate cancer detection using magnetic resonance imaging-transrectal ultrasound fusion biopsy: a retrospective cohort study. Indian J. Urol. IJU J. Urol. Soc. India 39, 297\u2013302 (2023).","journal-title":"Indian J. Urol. IJU J. Urol. Soc. India"},{"key":"77483_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.62347\/XBBI9870","volume":"14","author":"Z Liang","year":"2024","unstructured":"Liang, Z. et al. Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging. Am. J. Cancer Res. 14, 73\u201385 (2024).","journal-title":"Am. J. Cancer Res."},{"key":"77483_CR36","doi-asserted-by":"crossref","unstructured":"Durmaz, S. et al. The effects of prostate volume and PI-RADS category on optimal PSA-density thresholds for biopsy decision-making. Eur. Radiol. 36, 4503\u20134512 (2026).","DOI":"10.1007\/s00330-025-12272-y"},{"key":"77483_CR37","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.euf.2023.10.006","volume":"10","author":"F Pellegrino","year":"2024","unstructured":"Pellegrino, F. et al. Added value of prostate-specific antigen density in selecting prostate biopsy candidates among men with elevated prostate-specific antigen and PI-RADS \u22653 lesions on multiparametric magnetic resonance imaging of the prostate: a systematic assessment by PI-RADS score. Eur. Urol. Focus 10, 634\u2013640 (2024).","journal-title":"Eur. Urol. Focus"},{"key":"77483_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/JU.0000000000001424","volume":"205","author":"X Meng","year":"2021","unstructured":"Meng, X. et al. Follow-up of men with PI-RADS\u2122 4 or 5 abnormality on prostate magnetic resonance imaging and nonmalignant pathological findings on initial targeted prostate biopsy.  J. Urol. 205, 748\u2013754 (2021).","journal-title":"J. Urol."},{"key":"77483_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.eururo.2015.06.005","volume":"69","author":"X Meng","year":"2016","unstructured":"Meng, X. et al. Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur. Urol. 69, 512\u2013517 (2016).","journal-title":"Eur. Urol."},{"key":"77483_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.euo.2021.03.004","volume":"5","author":"M Ahdoot","year":"2022","unstructured":"Ahdoot, M. et al. Using prostate imaging-reporting and data system (PI-RADS) scores to select an optimal prostate biopsy method: a secondary analysis of the trio study. Eur. Urol. Oncol. 5, 176\u2013186 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"77483_CR41","doi-asserted-by":"crossref","unstructured":"Malewski et al. Prostate biopsy in the case of PIRADS 5-is systematic biopsy mandatory? J. Clin. Med. 12, 5612 (2023).","DOI":"10.3390\/jcm12175612"},{"key":"77483_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13244-024-01680-1","volume":"15","author":"Z Sun","year":"2024","unstructured":"Sun, Z. et al. Diagnostic performance of regional systematic biopsy for prostate cancer stratified by PI-RADS and histologic zones. Insights Imaging 15, 118 (2024).","journal-title":"Insights Imaging"},{"key":"77483_CR43","doi-asserted-by":"publisher","first-page":"235.e1","DOI":"10.1016\/j.urolonc.2020.12.015","volume":"39","author":"JN Drobish","year":"2021","unstructured":"Drobish, J. N. et al. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy? Urol. Oncol. 39, 235.e1\u2013e4 (2021).","journal-title":"Urol. Oncol."},{"key":"77483_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/JU.0000000000001766","volume":"206","author":"A Tafuri","year":"2021","unstructured":"Tafuri, A. et al. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS\u2122 5 and Prostate Specific Antigen Density Greater than 15.  J. Urol. 206, 289\u2013297 (2021).","journal-title":"J. Urol."},{"key":"77483_CR45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41391-023-00770-3","volume":"27","author":"A Zambon","year":"2024","unstructured":"Zambon, A. et al. Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors. Prostate Cancer Prostatic Dis. 27, 500\u2013506 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"77483_CR46","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00345-023-04382-3","volume":"41","author":"G Novara","year":"2023","unstructured":"Novara, G. et al. Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI\/transrectal ultrasonography fusion biopsy. World J. Urol. 41, 3239\u20133247 (2023).","journal-title":"World J. Urol."},{"key":"77483_CR47","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bju.16579","volume":"135","author":"L Boesen","year":"2025","unstructured":"Boesen, L., N\u00f8rgaard, N., Bisbjerg, R. & L\u00f8gager, V. Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy. BJU Int. 135, 465\u2013472 (2025).","journal-title":"BJU Int."},{"key":"77483_CR48","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.euo.2024.01.007","volume":"7","author":"HA Bourgeno","year":"2024","unstructured":"Bourgeno, H. A. et al. The added value of side-specific systematic biopsy in patients diagnosed by magnetic resonance imaging-targeted prostate biopsy. Eur. Urol. Oncol. 7, 1320\u20131326 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"77483_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jnci\/djae200","volume":"117","author":"MR Cooperberg","year":"2025","unstructured":"Cooperberg, M. R., Braun, A. E., Berlin, A., Kibel, A. S. & Eggener, S. E. When is prostate cancer really cancer? J. Natl. Cancer Inst. 117, 402\u2013405 (2025).","journal-title":"J. Natl. Cancer Inst."},{"key":"77483_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bju.15316","volume":"127","author":"A John","year":"2021","unstructured":"John, A., John, H., Catterwell, R., Selth, L. A. & Callaghan, M. O. Primary gleason grade and gleason grade group at positive surgical margins: a systematic review and meta-analysis. BJU Int. 127, 13\u201322 (2021).","journal-title":"BJU Int."},{"key":"77483_CR51","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.euo.2025.06.005","volume":"8","author":"K Shee","year":"2025","unstructured":"Shee, K. et al. The natural history of confirmed grade group 1 prostate cancer managed with active surveillance in the modern era. Eur. Urol. Oncol. 8, 1094\u20131100 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"77483_CR52","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.euo.2024.09.017","volume":"8","author":"T Fazekas","year":"2025","unstructured":"Fazekas, T. et al. Molecular correlates of prostate cancer visibility on multiparametric magnetic resonance imaging: a systematic review. Eur. Urol. Oncol. 8, 1352\u20131364 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"77483_CR53","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/JU.0000000000004069","volume":"212","author":"L Klotz","year":"2024","unstructured":"Klotz, L. The genomics and natural history of MRI-visible vs MRI-invisible prostate cancers: clinical implications.  J. Urol. 212, 494\u2013498 (2024).","journal-title":"J. Urol."},{"key":"77483_CR54","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/ijc.34743","volume":"154","author":"TK Lehto","year":"2024","unstructured":"Lehto, T. K. et al. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis. Int. J. Cancer 154, 926\u2013939 (2024).","journal-title":"Int. J. Cancer"},{"key":"77483_CR55","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.7150\/thno.23180","volume":"8","author":"P Li","year":"2018","unstructured":"Li, P. et al. Genes involved in prostate cancer progression determine MRI visibility. Theranostics 8, 1752\u20131765 (2018).","journal-title":"Theranostics"},{"key":"77483_CR56","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson, J. et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only.  N. Engl. J. Med. 387, 2126\u20132137 (2022).","journal-title":"N. Engl. J. Med."},{"key":"77483_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clgc.2022.04.001","volume":"20","author":"AG Wibmer","year":"2022","unstructured":"Wibmer, A. G. et al. MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. Clin. Genitourin. cancer 20, 319\u2013325 (2022).","journal-title":"Clin. Genitourin. cancer"},{"key":"77483_CR58","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","volume":"78","author":"V Stavrinides","year":"2020","unstructured":"Stavrinides, V. et al. Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study. Eur. Urol. 78, 443\u2013451 (2020).","journal-title":"Eur. Urol."},{"key":"77483_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/JU.0000000000004104","volume":"212","author":"P Lewicki","year":"2024","unstructured":"Lewicki, P. & Morgan, T. MRI-visible and -invisible prostate cancer.  J. Urol. 212, 499\u2013500 (2024).","journal-title":"J. Urol."},{"key":"77483_CR60","doi-asserted-by":"crossref","unstructured":"Salami S. S., et al. Biologic significance of magnetic resonance imaging invisibility in localized prostate cancer. JCO Precis. Oncol. 3, 54 (2019).","DOI":"10.1200\/PO.19.00054"},{"key":"77483_CR61","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euros.2022.07.006","volume":"43","author":"MJ Hagens","year":"2022","unstructured":"Hagens, M. J. et al. An magnetic resonance imaging-directed targeted-plus-perilesional biopsy approach for prostate cancer diagnosis: \u201cless is more. Eur. Urol. Open Sci. 43, 68\u201373 (2022).","journal-title":"Eur. Urol. Open Sci."},{"key":"77483_CR62","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/JU.0000000000001406","volume":"205","author":"Z Feuer","year":"2021","unstructured":"Feuer, Z. et al. Application of the PRECISION trial biopsy strategy to a contemporary magnetic resonance imaging-targeted biopsy cohort-how many clinically significant prostate cancers are missed?  J. Urol. 205, 740\u2013747 (2021).","journal-title":"J. Urol."},{"key":"77483_CR63","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/pros.24585","volume":"83","author":"I Yusim","year":"2023","unstructured":"Yusim, I. et al. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI\/ultrasound fusion prostate biopsy.  Prostate 83, 1255\u20131262 (2023).","journal-title":"Prostate"},{"key":"77483_CR64","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2015.12.052","volume":"70","author":"JP Radtke","year":"2016","unstructured":"Radtke, J. P. et al. Multiparametric magnetic resonance imaging (MRI) and MRI-transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur. Urol. 70, 846\u2013853 (2016).","journal-title":"Eur. Urol."},{"key":"77483_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re, O. et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.  Lancet Oncol. 20, 100\u2013109 (2019).","journal-title":"Lancet Oncol."},{"key":"77483_CR66","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","volume":"82","author":"WG Brisbane","year":"2022","unstructured":"Brisbane, W. G. et al. Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling. Eur. Urol. 82, 303\u2013310 (2022).","journal-title":"Eur. Urol."},{"key":"77483_CR67","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/s41391-021-00371-y","volume":"24","author":"A Stabile","year":"2021","unstructured":"Stabile, A. et al. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. Prostate Cancer Prostatic Dis. 24, 1137\u20131142 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"77483_CR68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.euros.2022.04.001","volume":"40","author":"MJ Hagens","year":"2022","unstructured":"Hagens, M. J. et al. Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy approach in prostate cancer diagnosis: a systematic review and meta-analysis. Eur. Urol. open Sci. 40, 95\u2013103 (2022).","journal-title":"Eur. Urol. open Sci."},{"key":"77483_CR69","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00345-023-04499-5","volume":"41","author":"AYM Lee","year":"2023","unstructured":"Lee, A. Y. M. et al. Intensive sampling of the umbra and penumbra improves clinically significant prostate cancer detection and reduces risk of grade group upgrading at radical prostatectomy. World J. Urol. 41, 2265\u20132271 (2023).","journal-title":"World J. Urol."},{"key":"77483_CR70","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.juro.2015.02.080","volume":"194","author":"J Le Nobin","year":"2015","unstructured":"Le Nobin, J. et al. Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis.  J. Urol. 194, 364\u2013370 (2015).","journal-title":"J. Urol."},{"key":"77483_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.euros.2024.03.006","volume":"63","author":"DL van den Kroonenberg","year":"2024","unstructured":"van den Kroonenberg, D. L. et al. The impact of omitting contralateral systematic biopsy on the surgical planning of patients with a unilateral suspicious lesion on magnetic resonance imaging undergoing robot-assisted radical prostatectomy for prostate cancer. Eur. Urol. open Sci. 63, 13\u201318 (2024).","journal-title":"Eur. Urol. open Sci."},{"key":"77483_CR72","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00261-023-03894-1","volume":"48","author":"M Ruan","year":"2023","unstructured":"Ruan, M., Wang, H., Li, X. & Song, G. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy. Abdom. Radiol. (N. Y.) 48, 2139\u20132147 (2023).","journal-title":"Abdom. Radiol. (N. Y.)"},{"key":"77483_CR73","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bju.16248","volume":"133","author":"M Chaloupka","year":"2024","unstructured":"Chaloupka, M. et al. Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort. BJU Int. 133, 548\u2013554 (2024).","journal-title":"BJU Int."},{"key":"77483_CR74","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.euf.2020.06.020","volume":"7","author":"S Tschirdewahn","year":"2021","unstructured":"Tschirdewahn, S. et al. Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging\/transrectal ultrasonography-fusion biopsy. Eur. Urol. focus 7, 1300\u20131307 (2021).","journal-title":"Eur. Urol. focus"},{"key":"77483_CR75","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eururo.2021.10.032","volume":"81","author":"J Immerzeel","year":"2022","unstructured":"Immerzeel, J. et al. Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists need to know. Part 4: transperineal magnetic resonance-ultrasound fusion guided biopsy using local anesthesia. Eur. Urol. 81, 110\u2013117 (2022).","journal-title":"Eur. Urol."},{"key":"77483_CR76","doi-asserted-by":"publisher","first-page":"270.e9","DOI":"10.1016\/j.urolonc.2024.08.004","volume":"43","author":"H Ayerra Perez","year":"2025","unstructured":"Ayerra Perez, H., Barba Abad, J. F., Argaluza Escudero, J., Extramiana Cameno, J. & Tolosa Eizaguirre, E. Development of prediction models based on risk scores for clinically significant prostate cancer on MRI\/TRUS fusion biopsy. Urologic Oncol. 43, 270.e9\u2013e18 (2025).","journal-title":"Urologic Oncol."},{"key":"77483_CR77","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaoncol.2017.5667","volume":"4","author":"S Mehralivand","year":"2018","unstructured":"Mehralivand, S. et al. A magnetic resonance imaging-based prediction model for prostate biopsy risk stratification. JAMA Oncol. 4, 678\u2013685 (2018).","journal-title":"JAMA Oncol."},{"key":"77483_CR78","doi-asserted-by":"crossref","unstructured":"Sigle, A. et al. Individualized decision making in transperineal prostate biopsy: should all men undergo an additional systematic biopsy? Cancers 14, 5230 (2022).","DOI":"10.3390\/cancers14215230"},{"key":"77483_CR79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen, A. C. et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology 296, 76\u201384 (2020).","journal-title":"Radiology"},{"key":"77483_CR80","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2214\/AJR.22.27421","volume":"219","author":"BR Salka","year":"2022","unstructured":"Salka, B. R., Shankar, P. R., Troost, J. P., Khalatbari, S. & Davenport, M. S. Effect of prostate MRI interpretation experience on PPV using PI-RADS version 2: a 6-year assessment among eight fellowship-trained radiologists. AJR Am. J. Roentgenol. 219, 453\u2013460 (2022).","journal-title":"AJR Am. J. Roentgenol."},{"key":"77483_CR81","doi-asserted-by":"publisher","first-page":"7.e19","DOI":"10.1016\/j.urolonc.2021.05.029","volume":"40","author":"MD Bevill","year":"2022","unstructured":"Bevill, M. D. et al. Number of cores needed to diagnose prostate cancer during MRI targeted biopsy decreases after the learning curve. Urologic Oncol. 40, 7.e19\u20137.e24 (2022).","journal-title":"Urologic Oncol."},{"key":"77483_CR82","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/pcan.2017.34","volume":"20","author":"B Calio","year":"2017","unstructured":"Calio, B. et al. Changes in prostate cancer detection rate of MRI-TRUS fusion vs systematic biopsy over time: evidence of a learning curve. Prostate Cancer Prostatic Dis. 20, 436\u2013441 (2017).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"77483_CR83","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009).","journal-title":"BMJ"},{"key":"77483_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int. J. Surg. 88, 105906 (2021).","journal-title":"Int. J. Surg."},{"key":"77483_CR85","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea, B. J. et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 358, j4008 (2017).","journal-title":"BMJ"},{"key":"77483_CR86","doi-asserted-by":"publisher","first-page":"e074495","DOI":"10.1136\/bmj-2022-074495","volume":"381","author":"A Izcovich","year":"2023","unstructured":"Izcovich, A., Chu, D. K., Mustafa, R. A., Guyatt, G. & Brignardello-Petersen, R. A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ 381, e074495 (2023).","journal-title":"BMJ"},{"key":"77483_CR87","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jclinepi.2019.12.020","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann, H. J. et al. GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J. Clin. Epidemiol. 122, 129\u2013141 (2020).","journal-title":"J. Clin. Epidemiol."},{"key":"77483_CR88","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2019.12.021","volume":"122","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann, H. J. et al. GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables. J. Clin. Epidemiol. 122, 142\u2013152 (2020).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77483-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:03:17Z","timestamp":1791504197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77483-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77483"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77483-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10623"}}